Struggling with the “Double-blinded placebo-controlled randomized controlled clinical trial for patients with Anal Intraepithelial Neoplasia (AIN),” Frantz Viral Therapeutics, a joint venture between Georgetown University Medical Center and Frantz Medical Group, faced numerous challenges while dealing with the trial phases. Moving ahead, they reached out to us with their concern over the ongoing challenges and sought help through Jeeva Clinical Trials Inc.'s eclinical solutions to accelerate their research. Learn how we accepted the challenges and, through our efficient and innovative solutions, assisted them in fulfilling their objectives from this case study: https://hubs.la/Q02gg2dj0 #RCT #clinicaltrials #AIN #healthtech #casestudy #randomizedclinicaltrial
Jeeva Clinical Trials Inc.’s Post
More Relevant Posts
-
"Ongoing Clinical Trials of Nonviral siRNA Therapeutics" by Owen Fenton and co-authors provides a clinically centered perspective. One of its standout features is an exhaustive summary table detailing ongoing siRNA clinical trials, including indications of use, targets, and associated NCT numbers. Beyond this, the review illuminates the nuances of in vivo siRNA delivery, discussing innovations in sequence modification, ligand conjugation, and nanoparticle packaging. A must-read for understanding the present challenges and future potential of siRNA therapies. 👇 https://lnkd.in/etsChYiB #RNA #siRNA #ClinicalTrials #DrugDelivery
To view or add a comment, sign in
-
Dianthus Therapeutics presented promising preclinical data for its autoimmune drug candidate, DNTH103, in models of myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy. The drug showed significant reductions in fatigue index for myasthenia gravis patients and restored neuronal conduction velocity in CIDP patients. DNTH103 targets the complement pathway with a selective mechanism of action to potentially lower the risk of infections compared to current treatment options. Dianthus is actively progressing with clinical trials for DNTH103, with Phase 2 trials underway and FDA clearance obtained for further studies in related conditions. #autoimmune #preclinicaldata #DNTH103 #neurologicaldisorders #clinicaltrials Read more here: https://lnkd.in/ehrVMURB BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.
web link
endpts.com
To view or add a comment, sign in
-
“We have to make the thing we’re bringing to market look more like something that the market understands how to value and how to buy. The market doesn’t understand exactly how to buy and deploy digital therapeutics." Our founder and CEO Aaron Gani recently spoke with STAT's Mario Aguilar about the evolution of RealizedCare and how our new digital care management solution for chronic pain aims to solve notable challenges within the digital therapeutics industry. Read more: https://hubs.la/Q02gYDgC0 #ChronicPain #DigitalCareManagement #DigitalHealth #CareManagement #DigitalTherapeutics
How digital therapeutics companies are improvising when insurance coverage isn’t guaranteed
To view or add a comment, sign in
-
At RealizedCare we've always believed that #digitaltherapeutics will improve access, improve health, and drive attendant savings in healthcare - all vital for improving population health and making our healthcare system sustainable. Digital therapeutics are poised to be one of the most transformative shifts in healthcare - shattering barriers of access and affordability. Read Mario Aguilar's insightful article to get a look at how RealizedCare, Freespira and Akili are evolving our business models to unlock the full value of DTx. (and we are just three examples - learn more at Digital Therapeutics Alliance!) Joseph Perekupka, Eddie Martucci, Andy Molnar
“We have to make the thing we’re bringing to market look more like something that the market understands how to value and how to buy. The market doesn’t understand exactly how to buy and deploy digital therapeutics." Our founder and CEO Aaron Gani recently spoke with STAT's Mario Aguilar about the evolution of RealizedCare and how our new digital care management solution for chronic pain aims to solve notable challenges within the digital therapeutics industry. Read more: https://hubs.la/Q02gYDgC0 #ChronicPain #DigitalCareManagement #DigitalHealth #CareManagement #DigitalTherapeutics
How digital therapeutics companies are improvising when insurance coverage isn’t guaranteed
To view or add a comment, sign in
-
Accomplished Board Member | Expert healthcare industry knowledge from scientific and commercial perspectives
Headed home from the 15th International Congress, after 2 full days of interesting and innovative presentations! The future is getting much brighter for patients with MPN, with many novel new therapeutics on the horizon! #MPN #clinicaltrials #patientsfirst
To view or add a comment, sign in
-
-
Senior Associate Dean for Academic & Student Affairs at USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Many people have seen the Calm app on T.V., but what do you know about the apps that are actually FDA cleared and require a prescription? Here is a brief review of those apps cleared for use in mental health disorders. #digitalhealth #pharmacy #USCMann
Dr. Kari Franson gives a brief overview of the importance of prescription digital therapies (PDTs), including some examples and why these therapies matter for both patients and clinicians. Watch the full presentation for by creating a free guest account! https://lnkd.in/eF-2iBvB Presented at the 2024 NEI Synapse, session titled "A New Script: Implementing Prescription Digital Therapeutics into Practice". Learn about upcoming NEI Meetings: https://lnkd.in/e_359k2J
Prescription Digital Therapies (PDTs)
To view or add a comment, sign in
-
Rob Etherington, our CEO, discusses innovation, regulatory, and investor challenges and opportunities in the #raredisease therapeutics market with Mike Ward of Clarivate. “We’ve seen regulatory flexibility start to occur for rare diseases and it is a godsend to the patients. More needs to be done… Rare diseases are important fights that we must continue every day,” says Rob. Tune in to hear Rob’s insights on rare disease therapies as Clene Nanomedicine, Inc. works to #EndALS: https://bit.ly/3VO0HQB
To view or add a comment, sign in
-
-
Drug development in early phase non-oncology clinical studies has undergone significant changes in recent years. In our latest white paper, IQVIA’s H. David Duque, MD, CPI and Liz Allen explore the factors that have driven these changes, analyze their impact on the design and execution of these studies, and examine the challenges facing clinical researchers today. Download now. https://bit.ly/3s40ZX0 #DrugDevelopment #ClinicalStudies #EarlyPhaseTrials
Paradigm Shifts in Early Phase Non-Oncology Studies in Healthy Volunteers and Patients
iqvia.com
To view or add a comment, sign in
-
On 28th August 2023, Stayble Therapeutics announced the enrollment of the first patient in the Company's Phase 1b clinical study with STA363 for the treatment of herniated discs. We are proud to support Stayble Therapeutics in this important project targeting patients suffering from disc herniation. Read more: https://lnkd.in/dFUzRT38 #discherniation #clinicalresearch #clinicaltrials #clinicaldevelopmentscherniation #clinicalresearch #clinicaltrials #clinicaldevelopment
To view or add a comment, sign in
-
Today Halia’s CEO David Bearss Ph.D. presented at the 5th Inflammasome Therapeutics Summit in Boston about Halia’s efforts to combat chronic inflammation by inhibiting the inflammasome NLRP3. Dave discussed the early clinical evaluation of Halia’s NLRP3 inhibitor, HT-6184, and its activity as a selective, orally bioavailable, allosteric inhibitor of Nek7/NLRP3. To read more about the results of Halia’s completed Phase 1 clinical trial (NCT05447546), see today’s news release here: https://prn.to/3sV4T4T For more information about the Summit, go to: https://bit.ly/40UyYOI #inflammasome #chronicinflammation #inflammasometherapeuticssummit #NLRP3 #therapeutics
To view or add a comment, sign in
-